DRNA
Dicerna Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Market Cap: 2.99 Billion
Primary Exchange: NASDAQ
Website: www.dicerna.com
Shares Outstanding: 78.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0915623153988145
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 3113 trading days
From: 2014-01-30 To: 2021-12-27
Lowest Point:
Dicerna(TM) Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
via: Business Wire at 2019-06-13 03:30:00:000
Steven Kates, Ph.D., Joins Company as Vice President, Regulatory Affairs David Caponera Appointed Head of Patient Advocacy and Patient Services Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicer… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|